The most common mechanism of CML resistance occurs because of mutations to the ATP binding site of the BCR-ABL fusion protein within the tumor. This subject is left to others as many overviews are available, focusing on the mutations themselves or the drugs that can overcome certain resistance mutations [13-17]. This evidence concerns the gene BCR and neoplasm.